A recent study published in the European Pharmaceutical Review has revealed that a combination therapy can significantly improve the collection of stem cells from donors.
The therapy utilizes Plerixafor, a CXCR4 antagonist, in conjunction with granulocyte-colony stimulating factor (G-CSF), which helps mobilize stem cells from bone marrow to peripheral blood.
The study found that this combination therapy was more effective than G-CSF alone, enabling better stem cell yields and potentially improving the success rate of stem cell transplants for patients with blood disorders and certain types of cancer.
The research involved 40 patients who had previously undergone unsuccessful stem cell mobilization using G-CSF alone. These patients were given the combination therapy, which resulted in successful stem cell mobilization for 95% of the patients.
The results suggest that Plerixafor is a viable option to enhance G-CSF’s efficacy, making it a potentially valuable tool in the realm of stem cell transplantation.
Furthermore, the study’s findings may lead to an improved standard of care for patients requiring stem cell transplants, as well as increased accessibility to this life-saving treatment.